))
ACRUX LIMITED (ACR) - Transforming Topical Pharmaceuticals: CEO Michael Kotsanis on FDA Approvals, Market Strategy, and R&D Innovations
Manage episode 433896279 series 3570035
Sisällön tarjoaa Andrew Musgrave. Andrew Musgrave tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Curious about the future of topical pharmaceuticals? Michael Kotsanis, CEO of Acrux Limited, joins us to uncover the company's strategic endeavors and recent successes. With over 25 years of industry experience, Michael offers valuable insights into Acrux’s focus on developing and commercializing topical generic products for the lucrative US market, valued at $16 billion. He also shares the exciting news of their recent launch of Dapsone 5% Gel and the promising market response, along with updates on three other products currently under FDA review.
Get a behind-the-scenes look at Acrux’s robust research and development efforts, supported by their GMP-licensed facility and collaborations with contract manufacturers worldwide. Learn about the intricate process of drug approval and how Acrux aims to build a sustainable revenue stream through consistent product submissions and launches. This episode is packed with fascinating details about the competitive pharmaceutical landscape and Acrux's future prospects. Don't miss this in-depth conversation with one of the industry's key players!
57 jaksoa
Jaa
